Risco-Risco, C.; Henriquez-Camacho, C.; Herrera-Rueda, M.; Barberán, J.; Andaluz-Ojeda, D.
Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis. Antibiotics 2024, 13, 1048.
https://doi.org/10.3390/antibiotics13111048
AMA Style
Risco-Risco C, Henriquez-Camacho C, Herrera-Rueda M, Barberán J, Andaluz-Ojeda D.
Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis. Antibiotics. 2024; 13(11):1048.
https://doi.org/10.3390/antibiotics13111048
Chicago/Turabian Style
Risco-Risco, Carlos, César Henriquez-Camacho, Marta Herrera-Rueda, José Barberán, and David Andaluz-Ojeda.
2024. "Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis" Antibiotics 13, no. 11: 1048.
https://doi.org/10.3390/antibiotics13111048
APA Style
Risco-Risco, C., Henriquez-Camacho, C., Herrera-Rueda, M., Barberán, J., & Andaluz-Ojeda, D.
(2024). Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis. Antibiotics, 13(11), 1048.
https://doi.org/10.3390/antibiotics13111048